(Corrects November 6 story to say Novo expects an estimated negative low single-digit impact, not global sales to decline by low single-digit percentage)

(Reuters) -Novo Nordisk said it currently expects an estimated negative low single-digit impact to global sales growth in 2026 after the drugmaker unveiled a deal on Thursday to slash prices of popular GLP-1 weight-loss drugs for U.S. government-backed insurance programs and cash payers.